Patients with uncontrolled type 2 asthma may underreport symptoms, normalize limitations, or mask poor control through daily workarounds. Fortunately, patient education, open-ended questioning, active listening, and structured tools like symptom[…]
Announcement
INHALE’s annual in-person Fall Regional meetings have been scheduled and registration is available now in the Admin Portal. As a reminder: Dates & Times All meetings run from 5:30 – 8:00[…]
AstraZeneca’s press release announces that the FDA has approved Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) as the first and only single‑inhaler triple‑combination maintenance therapy for asthma in patients 12 years and older[…]
The Asthma and Allergy Foundation of America (AAFA) has published a new resource: “Health Insurance Marketplace Guide for Asthma and Allergies for 2026.” This comprehensive guide is designed to help[…]